Leucapher

Leucocytapheresis – cellular adsorption, for the treatment of autoimmune inflammatory diseases

Leucapher is a multi-therapeutic platform designed to perform extracorporeal treatments directly on whole blood in patients with Inflammatory Bowel Diseases (IBD) or other inflammatory conditions:

  • Leukocytapheresis
  • Hemoperfusion with predilution

The goal is to promote the removal of leukocytes and lymphocytes from the bloodstream, thereby combating inflammatory diseases.

Leucapher: Dedicated therapy system for Critical Care
Leucapher Logo: Dedicated Therapy System for Critical Care

Therapies and treatments

In Leucapher’s leukocytapheresis mode, the system performs adsorption treatments of leukocytes, including neutrophils, monocytes, and lymphocytes. This adsorption is facilitated by the Leukocyte Adsorber (LA25), a cartridge made of Hydrophilic Polysulfone, known for its high biocompatibility and ability to adsorb these cells from the circulation.

Thanks to a pre-dilution system, outpatient treatments are feasible using peripheral access, ensuring minimally invasive procedures with maximum safety.

Summary of Leukocytapheresis:

  • Minimally invasive treatment with peripheral needle access
  • High biocompatibility
  • Automatic pre-dilution
  • Anticoagulation with citrate
  • Blood pump flow rate between 5 and 150 ml/min
  • Complete set of color-coded lines
  • Simple and fast assembly
Leucapher Leucocytapheresis

Thanks to the presence of a peristaltic pump capable of operating between 5 and 150 ml/min, Leucapher is also designed to perform Hemoperfusion treatments with CytoSorb® cartridges, dedicated to the adsorption of molecules responsible for the development of various pathological conditions directly from whole blood.

The reduced pump flows and the automatic pre-dilution system make the treatment minimally invasive and allow the use of peripheral needles.

Leucapher Leucocytapheresis